Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
ATP-focused company updates recent drug development and corporate activities
March 24th, 2005
Duska Therapeutics, Inc., (DSKT) reported on the status of certain of its drug development and corporate activities. ATPace is Duska's liquid formulation of adenosine 5'-triphosphate (ATP) that is being developed as a diagnostic test for identification of an abnormally slow heart rate (bradycardia) as the cause of syncope (or fainting). Duska has selected 20 principal investigators and their clinical sites in the U.S. and Canada to participate in its recently initiated phase II clinical trial of ATPace. Enrollment of patients in this trial is anticipated to commence within approximately 30-60 days. ATPotent is Duska's liquid formulation of ATP that...
Source: Women's Health Weekly (2005-03-24)
|
